Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
34 Leser
Artikel bewerten:
(0)

Research and Markets - Global Pain Management Devices Market Value of USD 4.64 Billion by 2021 - Trends, Technologies & Opportunities Report 2016-2021 - Key Vendors: Halyard Health, St. Jude Medical, Medtronic

DUBLIN, June 17, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Pain Management Devices Market by Device Type (Neurostimulation, SCS, TENS, RF Ablation, Infusion Pumps), Application (Cancer, Neuropathy, Musculoskeletal, Migraine, Facial), by Mode of Purchase (OTC, Prescription-Based) - Global Forecasts to 2021" report to their offering.

The global pain management devices market is forecast to reach a value of USD 4.64 Billion by 2021. The growth in this market is primarily driven by factors such as the presence of a large patient population base and adverse effects associated to the use of pain medications.

Based on type, the pain management devices market is categorized into neurostimulation devices (transcutaneous electrical nerve stimulation (TENS) and spinal cord stimulation (SCS)), ablation devices (RF ablation and cryoablation), and analgesic infusion pumps (intrathecal and external infusion pumps). The neurostimulation devices segment is expected to account for the largest share of the market in 2016. This can majorly be attributed to the cost-effectiveness of neurostimulation devices, high efficacy of TENS and SCS devices in alleviating chronic pain, and availability of reimbursement for SCS therapy in developed countries.

On the basis of applications, the pain management devices market is segmented into neuropathic pain, cancer pain, facial pain and migraine, musculoskeletal pain, and other applications (pregnancy/labor and menstrual pain, sports injuries, post-operative pain, and trauma pain). The neuropathic pain segment is estimated to witness the highest growth during the forecast period, primarily due to the high prevalence of diseases resulting in neuropathic pain.

On the basis of mode of purchase, the market is categorized into over-the-counter and prescription-based pain management devices. The prescription-based devices segment is estimated to command a larger share, majorly due to the longer market presence of these devices with established safety and efficacy profiles and their long-term cost effectiveness.

Companies Mentioned:

  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Halyard Health, Inc.
  • Hospira, Inc. (A Subsidiary of Pfizer Inc.)
  • Medtronic PLC
  • Neurotech Na, Inc. (A Subsidiary of Theragen LLC)
  • Nevro Corp.
  • ST. Jude Medical, Inc.
  • Smiths Medical

Report Structure:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Insights

7 Global Pain Management Devices Market, By Type

8 Global Pain Management Devices Market, By Application

9 Global Pain Management Devices Market, By Mode of Purchase

10 Pain Management Devices Market, By Region

11 Competitive Landscape

12 Company Profiles

13 Appendix

For more information visit http://www.researchandmarkets.com/research/lfjt9d/pain_management

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.